There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...

By Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...